title: Genome-wide array-based comparative genomic hybridization of diffuse large B-cell lymphoma: comparison between CD5-positive and CD5-negative cases.
abstract: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma and exhibits aggressive and heterogeneous clinical behavior. To genetically characterize DLBCL, we established our own array-based comparative genomic hybridization and analyzed a total of 70 cases [26 CD-positive (CD5+) DLBCL and 44 CD5-negative (CD5-) DLBCL cases]. Regions of genomic aberrations observed in >20% of cases of both the CD5+ and CD5- groups were gains of 1q21-q31, 1q32, 3p25-q29, 5p13, 6p21-p25, 7p22-q31, 8q24, 11q23-q24, 12q13-q21, 16p13, 18, and X and losses of 1p36, 3p14, 6q14-q25, 6q27, 9p21, and 17p11-p13. Because CD5 expression marks a subgroup with poor prognosis, we subsequently analyzed genomic gains and losses of CD5+ DLBCL compared with those of CD5-. Although both groups showed similar genomic patterns of gains and losses, gains of 10p14-p15 and 19q13 and losses of 1q43-q44 and 8p23 were found to be characteristic of CD5+ DLBCL. By focusing on the gain of 13q21-q34 and loss of 1p34-p36, we were also able to identify prognostically distinct subgroups among CD5+ DLBCL cases. These results suggest that array-based comparative genomic hybridization analysis provides a platform of genomic aberrations of DLBCL both common and specific to clinically distinct subgroups.
authors.affiliation: Division of Molecular Medicine, Aichi Cancer Center Research Institute, Aichi, Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Tagawa
authors.forename: Shinobu
authors.initials: S
authors.lastname: Tsuzuki
authors.forename: Ritsuro
authors.initials: R
authors.lastname: Suzuki
authors.forename: Sivasundaram
authors.initials: S
authors.lastname: Karnan
authors.forename: Akinobu
authors.initials: A
authors.lastname: Ota
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Kameoka
authors.forename: Miyuki
authors.initials: M
authors.lastname: Suguro
authors.forename: Keitaro
authors.initials: K
authors.lastname: Matsuo
authors.forename: Motoko
authors.initials: M
authors.lastname: Yamaguchi
authors.forename: Masataka
authors.initials: M
authors.lastname: Okamoto
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Morishima
authors.forename: Shigeo
authors.initials: S
authors.lastname: Nakamura
authors.forename: Masao
authors.initials: M
authors.lastname: Seto
mesh_terms: D018956:CD5 Antigens / Q000096:biosynthesis* / Q000276:immunology; D045744:Cell Line, Tumor; D000090266:Chromobox Protein Homolog 5; D002869:Chromosome Aberrations; D005260:Female; D018628:Gene Dosage; D020869:Gene Expression Profiling; D006801:Humans; D016393:Lymphoma, B-Cell / Q000235:genetics* / Q000276:immunology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000235:genetics* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009693:Nucleic Acid Hybridization / Q000379:methods; D011379:Prognosis
chemical_list: C000715594:CBX5 protein, human; D018956:CD5 Antigens; D000090266:Chromobox Protein Homolog 5